Management of Coronary Artery Disease with Elevated Lipoprotein(a)

Introduction to Lipoprotein(a) Management

The European Society of Cardiology recommends aggressive LDL-cholesterol reduction as the primary evidence-based treatment strategy for coronary artery disease management, with LDL-C serving as the main therapeutic target across all major international guidelines 1, 2
The American College of Cardiology identifies LDL-C as the primary target of therapy, with elevated Lipoprotein(a) [Lp(a)] being an independent risk factor that increases cardiovascular risk 1, 2

For patients with established coronary artery disease (very high risk), the European Society of Cardiology recommends a target LDL-C <1.8 mmol/L (70 mg/dL) or achieve at least 50% reduction from baseline, representing Class I, Level B evidence 1
For patients at high cardiovascular risk, the European Society of Cardiology recommends a target LDL-C <2.6 mmol/L (100 mg/dL) or achieve at least 50% reduction from baseline 1
The American College of Cardiology recommends even lower LDL-C goals, with optimal target <70 mg/dL, for patients with elevated Lp(a) 3, 4

Lipoprotein(a) is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease, with 70-90% of Lp(a) variation determined by genetics rather than lifestyle 4
Elevated Lp(a) increases risk through multiple mechanisms, including promoting atherosclerosis, causing inflammation, and having anti-fibrinolytic/pro-thrombotic effects 4

Niacin reduces Lp(a) by 30-35% at doses up to 2000 mg/day, and is the most effective conventional medication for Lp(a) reduction 3, 5
PCSK9 inhibitors reduce Lp(a) by approximately 25-30% and are particularly valuable in patients with both elevated LDL-C and elevated Lp(a) 3, 4, 5

Patients with familial hypercholesterolemia and elevated Lp(a) face compounded risk and may require more intensive LDL-C reduction with PCSK9 inhibitors or lipoprotein apheresis 3, 5
Patients with chronic kidney disease have substantially increased Lp(a) levels and may require statin or statin/ezetimibe combination therapy 1, 3

Initial follow-up should include rechecking lipid panel in 4-6 weeks after initiating or adjusting therapy, and assessing achievement of LDL-C goal and tolerability 4, 5
Secondary targets include non-HDL-C goal <130 mg/dL (3.4 mmol/L), which is 30 mg/dL higher than the LDL-C goal, and non-HDL-C goal <2.6 mmol/L (100 mg/dL) for very high-risk patients 1, 4, 5